Lung Cancer
Conditions
Interventions
Control group:Sufentanil 0.03 µg/kg/h Dexamethasone 15 mg Ondansetron 12 mg
Experimental group:Sufentanil 0.015 µg/kg/h, Targin 1.5 µg/kg/h, Dexamethasone 15 mg, Ondansetron 12 mg
Sponsors
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. No gender restriction 2. Age 18-65 years 3. BMI 18-30 kg/m² 4. ASA class I–III 5. Elective single-port or two-port unilateral thoracoscopic segmentectomy or lobectomy.
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1.Patients with contraindications to thoracic paravertebral blockade; 2.Severe heart, lung, liver or kidney diseases; 3.Patients with known or suspected gastrointestinal obstruction, including paralytic ileus; 4.Chronic pain, alcoholism, mental disorders or opioid dependence; 5.Mental illnesses or communication disorders; 6.Severe sleep and cognitive disorders, with an Athens Insomnia Scale (AIS) score >= 6 and a Mini-Mental State Examination (MMSE) score <=27 after admission; 7.Patients with hypersensitivity or addiction to the active ingredient or excipients of tegileridine; 8.Patients who refuse to participate in this study; 9.Conversion to open thoracotomy during the operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Recovery Score(QoR-15);Athens Insomnia Scale (AIS) score;Confusion Assessment Method (CAM) score; | — |
Countries
China
Contacts
Public ContactJiang Ming
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Outcome results
None listed